The prognosis with untreated bladder tumors

Prout, George R.; Marshall, Victor F.

doi:10.1002/1097-0142(195605/06)9:3<551::aid-cncr2820090319>3.0.co;2-2

Cited by 139 publications

(67 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 In contrast, muscle-invasive UC (clinical stage ≥T2) is a lethal malignancy that, when untreated, results in death within 2 years of the diagnosis in over 85% of patients. 6 A definitive surgical approach that involves removing the primary bladder tumour and regional lymph nodes results in excellent long-term survival rates. 7 However, despite improved outcomes with neoadjuvant cisplatin-based combined chemotherapy, almost half of these patients will relapse with metastatic disease.…”

Section: Introductionmentioning

confidence: 99%

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Ehdaie

Smith

Theodorescu

2013

CUAJ

View full text Add to dashboard Cite

The past decade has provided an improved understanding of the molecular mechanism of bladder cancer by defining distinct pathways in tumorigenesis and progression. Advances in technologies, such as high-throughput transcript profiling, microarrays and proteomics, offer a systematic approach to identifying targets for bladder cancer diagnostics and drug discovery. This review presents a select outline of the advances in the development of biomarkers and targets for patient prognosis and therapy selection. This paper describes a representative cohort of recent studies that have the potential to significantly impact the management of muscle invasive and metastatic urothelial carcinoma of the bladder. Space constraints do not permit this review to be comprehensive and we apologize to the authors whose work we do not cite.

show abstract

Section: Introductionmentioning

confidence: 99%

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Ehdaie

Smith

Theodorescu

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…[16] İnvaziv mesane tümörü ölümcül bir hastalıktır ve tedavi edilmediği takdirde olguların %85'i 2 yıl içerisinde hastalık nedeniyle ölmektedir. [17] Buna karşın son yıllarda yayınlanan serilerde radikal sistektomi operasyonu ile invaziv mesane kanserinin bu ölümcül doğal seyrinin değiştirildiği ve sistektomi sonrası 10 yıllık sağ kalım oranlarının %50 ile %66 arasında değiştiği bildirilmektedir. [18] İnvazyon ve diferansiasyon derecesi mesane kanserinin prognozunu belirleyen önemli faktörlerdir.…”

Section: Discussionunclassified

The effect of gender on oncological outcomes in patients who have undergone radical cystectomy due to bladder cancer

Şefik¹,

Görgel²,

Balcı³

et al. 2012

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate the effect of gender on oncologic results in patients who have undergone radical cystectomy due to bladder cancer. Materials and methods:We retrospectively reviewed data from 460 patients who had radical cystectomy due to bladder cancer in our clinic. A total of 420 of the patients were men, and 40 patients were women. We evaluated the tumor type, tumor stage, tumor grade, lymph node involvement status, complications and survival rates of the females. These parameters were compared to male cystectomy data. Results:The median age of male and female patients was 60.59±8.966 and 63.2±7.816, respectively (p= 0.076). In total, 79.4% of the males and 70.3% of females had transitional cell cancer (p= 0.192). The detection frequencies for pT1, pT2, pT3 vs. pT4 stage tumors in males and females was 18%, 34.2%, 33.4% vs. 14% and 2.8%, 33.3%, 41.7%, 22.2%, respectively. The percentage of the lymph node involvement in female and male patients was 48.5% and 23.9% (p= 0.02). The grade 3 tumor involvement in female and male patients was 80.6% and 72.7% (p= 0.621). In females, the bladder-confined tumor percentage was 22.2% and males rate was 48.3% (p= 0.04). In terms of overall complications, no significant differences were found between males and females. Disease-specific survival (DSS) was 115±42.2 months in males and 18±2.14 months in females. Three-year DSS was 61.4% in males and 15.3% in females (p= 0.013). Median overall survival was 47±11.789 months in males and 18±1.581 months in females. Three-year overall survival was 53.2% for males and 11.4% for females. A significant difference was found between males and females (p= 0.013). Conclusion:In this study, we found that females present worse disease specific and overall survival rates than males due to poor prognostic factors such as lymph node involvement and the higher prevalence of extravesical disease in female patients.Key words: Bladder cancer; gender; radical cystectomy. ÖZETAmaç: Bu çalışmanın amacı mesane tümörü nedeniyle radikal sistektomi yapılan hastalarda cinsiyetin onkolojik sonuçlara etkisini değerlendirmektir. Gereç ve yöntem:Kliniğimizde mesane tümörü nedeniyle radikal sistektomi uygulanan 460 hastanın verileri retrospektif olarak incelendi. 420 erkek ve 40 kadın hasta çalışmaya dahil edildi. Kadın sistektomi olgularının tümör tipi, tümör evreleri, tümör derecesi, lenf nodu tutulum oranları, komplikasyonlar ve sağ kalım verileri değerlendirildi. Bu parametreler açısından erkek sistektomi olgularıyla karşılaştırıldı. Bulgular: Erkek hastaların yaş ortalaması 60.59±8.966, kadın hastaların yaş ortalaması ise 63.2±7.816 idi (p= 0.076). Erkek hastaların %79.4'ü transizyonel hücreli kanser iken kadın hastalarda bu oran %70.3 idi (p= 0.192). Kadın hastalarda pT1, pT2, pT3 ve pT4 evrelerinde tümör saptanma sıklığı sırasıyla %2.8, %33.3, %41.7, %22.2 iken erkeklerde bu oranlar sırasıyla %18, %34.2, %33.4 ve %14 idi. Lenf nodu tutulumu açı-sından olgular değerlendirildiğinde kadın hastalarda lenf notu tutul...

show abstract

“…Invasive bladder carcinoma is a fatal disease (i.e. nearly 85% mortality rate is seen in untreated patients) (8). Currently, radical cystectomy is the gold-standrad in treating invasive bladder tumors (3).…”

Section: Discussionmentioning

confidence: 99%

Analysis of Prognostic Factors in Bladder Carcinoma Treated With Radical Cystectomy

Baltacı¹,

Göğüş²,

Türkölmez³

et al. 2008

Ankara Üniversitesi Tıp Fakültesi Mecmuası

View full text Add to dashboard Cite

Aim: To evaluate variable prognostic factors which might aff ect disease-specific survival in patients who have undergone radical cystectomy and pelvic lymphadenectomy for bladder carcinoma. Methods:We retrospectively reviewed 241 consecutive patients with invasive bladder carcinoma between 1990 and 2008, all had radical cystectomy. The clinical and pathological data and clinical outcome were evaluated. The Chi-square test was used to determine the significance of the relationship between the clinical and pathological findings. While disease-specific survival and the association between patient`s parameters and survival were analyzed using Kaplan-Meier method and long-rank test respectively.Results: Considering the type of urinary diversion, 97 patients had ileal conduit; 58 patients had orthotopic bladder using ileal segment; and orthotopic mainz pouch was applied to 43 patients. While ureterocutaneostomy and ureterosigmoidostomy were the choice in 22 and 21 patients respectively. The mean age of the patients at receipt of the surgical procedure was 59.8 years (range from 29 to 83 years) and the mean follow-up interval was 34 months (median follow up: 22, SD: 36.66; range from 1 to 175) for patients alive at last follow-up. According to the pathological stage, the 5-year survival rate was found to be 72.9%, %77.6%, 48.0%, 25.4% and 28.8% for pT0, pT1, pT2, pT3 and pT4 respectively. (Figure 1; log-rank test, p<0.001). Moreover, it is found that 6.5%, 11.5%, 16.7%, 49.1% and 48.6% were the local recurrence and/or metastasis rate for pT0, pT1, pT2, pT3 and pT4 respectively (p<0.001). It is seen that lymph node involvement obviously rise with the advance in pathological stage. In another word, the rate of having nodal metastasis was significantly higher in patients with pT3 or more (pT3: 26.3%, pT4: 20%) than in those with pT2 or less (pT0 and pT1: 0%, pT2: 6.1%), ( p<0.001). On univariate analysis, patient`s age, presence of tumor-related hydronephrosis, lymph node status, pathological stage and grade were significant predictors of disease-specific survival. Conclusions:In this study, it is clearly shown that good results could be obtained if radical cystectomy is the treatment of choice for patients with early diagnosed invasive bladder carcinoma.Key Words: bladder cancer, radical cystectomy, prognosis Amaç: İnvaziv mesane tümörlerinin tedavisinde bugün için standart tedavi yöntemi radikal sistektomidir. Bu çalışmada, invaziv mesane kanseri nedeniyle radikal sistektomi yapılan 241 hastadaki cerrahi deneyimlerimiz ve uzun dönem takip sonuçlarımız sunulmaktadır. Materyal ve Metodlar:Kliniğimizde 1990 yılından itibaren invaziv mesane kanseri nedeniyle radikal sistektomi yapılan 241 hastanın (214 erkek, 27 bayan) kayıtları retrospektif olarak incelenmiştir. Klinik ve patolojik verilerle birlikte, hastaların takip sonuçları da değerlendirilmiştir. Kategorik değişkenler arasındaki ilişkilerin araştırılmasında ki-kare testi kullanılmıştır. Sağkalım oranları Kaplan-Meier metodu ile, hastaların özellikleri ve sağkalım ara...

show abstract

The prognosis with untreated bladder tumors

Cited by 139 publications

References 5 publications

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat

The effect of gender on oncological outcomes in patients who have undergone radical cystectomy due to bladder cancer

Analysis of Prognostic Factors in Bladder Carcinoma Treated With Radical Cystectomy

Contact Info

Product

Resources

About